Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps - CNBC
- Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps CNBC
- What Novo Nordisk’s disappointing trial results mean for the obesity drug market STAT
- 'A worst case scenario for Novo': Read the market reaction to CagriSema trial Reuters.com
- There’s a New Obesity King The Wall Street Journal